Literature DB >> 3115236

Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.

J R Mendell, M A Province, R T Moxley, R C Griggs, M H Brooke, G M Fenichel, J P Miller, K K Kaiser, W King, J Robison.   

Abstract

Between 1979 and 1987 we documented the natural history of Duchenne muscular dystrophy in 170 patients, aged from 3 to 23 years, by making serial measurements in over 5000 individual evaluations. This database makes it possible to design and conduct therapeutic trials using natural history controls. Such trials do not replace the need for randomized placebo-controlled trials of promising agents but they do require fewer patients, are cost-effective, and permit the use of high-risk therapy where toxicity monitoring may be important. Natural history-controlled trials, therefore, may serve as a screening method for new therapeutic agents. Drugs showing a significant benefit can then be evaluated in a randomized controlled trial.

Entities:  

Mesh:

Year:  1987        PMID: 3115236     DOI: 10.1001/archneur.1987.00520200012009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Tissue- and case-specific retention of intron 40 in mature dystrophin mRNA.

Authors:  Atsushi Nishida; Maki Minegishi; Atsuko Takeuchi; Emma Tabe Eko Niba; Hiroyuki Awano; Tomoko Lee; Kazumoto Iijima; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2015-04-02       Impact factor: 3.172

2.  Assessment of intramuscular lipid and metabolites of the lower leg using magnetic resonance spectroscopy in boys with Duchenne muscular dystrophy.

Authors:  Donovan J Lott; Sean C Forbes; Sunita Mathur; Sean A Germain; Claudia R Senesac; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Neuromuscul Disord       Date:  2014-04-13       Impact factor: 4.296

3.  Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment.

Authors:  Joerg-Patrick Stübgen; Annette Stipp
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

4.  CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.

Authors:  Christopher F Spurney; Carolina Tesi Rocha; Erik Henricson; Julaine Florence; Jill Mayhew; Ksenija Gorni; Livia Pasquali; Alan Pestronk; Gerard R Martin; Fengming Hu; Lei Nie; Anne M Connolly; Diana M Escolar
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

5.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors:  Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-17       Impact factor: 11.454

6.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

7.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

8.  Duchenne muscular dystrophy quantification: a multivariate analysis of surface EMG.

Authors:  A Priez; J Duchene; F Goubel
Journal:  Med Biol Eng Comput       Date:  1992-05       Impact factor: 2.602

9.  The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.

Authors:  Erik K Henricson; R Ted Abresch; Avital Cnaan; Fengming Hu; Tina Duong; Adrienne Arrieta; Jay Han; Diana M Escolar; Julaine M Florence; Paula R Clemens; Eric P Hoffman; Craig M McDonald
Journal:  Muscle Nerve       Date:  2013-05-06       Impact factor: 3.217

10.  Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

Authors:  Anne M Connolly; Julaine M Florence; Mary M Cradock; Elizabeth C Malkus; Jeanine R Schierbecker; Catherine A Siener; Charlie O Wulf; Pallavi Anand; Paul T Golumbek; Craig M Zaidman; J Philip Miller; Linda P Lowes; Lindsay N Alfano; Laurence Viollet-Callendret; Kevin M Flanigan; Jerry R Mendell; Craig M McDonald; Erica Goude; Linda Johnson; Alina Nicorici; Peter I Karachunski; John W Day; Joline C Dalton; Janey M Farber; Karen K Buser; Basil T Darras; Peter B Kang; Susan O Riley; Elizabeth Shriber; Rebecca Parad; Kate Bushby; Michelle Eagle
Journal:  Neuromuscul Disord       Date:  2013-05-28       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.